![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Innosis Ecological Ag | TG:IVX | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
BW20030514002068 20030514T125602Z UTC ( BW)(IVAX-CORPORATION)(IVX) IVAX Corporation Announces Settlement; IVAX Allowed To Begin Marketing Pergolide In Early September Business Editors UK REGULATORY NEWS LONDON--(BUSINESS WIRE)--May 14, 2003-- MIAMI--(BUSINESS WIRE)--May 14, 2003--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) today announced that it has entered into a settlement of patent litigation with Amarin Corporation plc which will allow IVAX to begin marketing pergolide mesylate, the generic equivalent of Permax(R), in early September. The litigation related to two U.S. patents licensed to Amarin by Eli Lilly and Company when Amarin acquired the exclusive U.S. license rights to Permax tablets from Elan Corporation. Under the terms of the settlement, IVAX receives a nonexclusive U.S. sublicense from Amarin and Lilly to the two patents beginning September 2, 2003, in return for payments to Amarin during the first six months of sales of the product following final approval by the FDA. IVAX previously announced that its ANDA for pergolide mesylate tablets in .05mg, .25mg and 1mg strengths received tentative approval from the FDA. This product will be sold through the company's wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Pergolide mesylate is used as adjunctive treatment in connection with Parkinson's disease. Pergolide's active pharmaceutical ingredient is produced at IVAX' facility in the Czech Republic. IVAX currently has 38 ANDAs pending at the FDA. The company is continuing its aggressive filing schedule for new ANDA submissions. IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally. Copies of this and other news releases may be obtained free of charge from IVAX' website at http://www.ivax.com. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements, including the statements regarding IVAX' pending ANDAs and filing schedule for ANDA submissions, involve risks and uncertainties which may affect the company's business and prospects, including the risks that final approval of IVAX' ANDA for pergolide mesylate tablets in .05mg, .25mg and 1mg strengths may be delayed or not received at all; that launch of the tablets may be delayed; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; that IVAX may not receive approval of its pending ANDAs, or that if approved, the products will not be successfully commercialized; that IVAX may not file any additional ANDAs; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Permax(R) is a registered trademark of Eli Lilly and Company. Short Name: IVAX Corporation Category Code: MSC Sequence Number: 00004778 Time of Receipt (offset from UTC): 20030514T133319+0100 --30--ac/uk* CONTACT: IVAX Corporation KEYWORD: UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL SOURCE: IVAX Corporation Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
1 Year Innosis Ecological Chart |
1 Month Innosis Ecological Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions